GlassScriptPhysician profile
Gaea Pope-Daum
NPI 1679878193
$2,630.34
in general payments reported to CMS, 2019-2025
18 companies · $462 in 2025
The $462 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $332 · 2024: $1,837 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,630.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $603.61 | 2023-2025 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $423.21 | 2023-2025 | Spravato, Invega Sustenna |
| Abbvie INC. | $296.23 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $288.68 | 2024-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $164.89 | 2023-2025 | Ingrezza |
| Lundbeck LLC | $161.85 | 2024 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $124.26 | 2023-2025 | Auvelity |
| Sage Therapeutics, LLC | $93.04 | 2024-2025 | Zurzuvae |
| Alkermes, INC. | $79.96 | 2024 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $79.05 | 2023-2024 | Rexulti |
| Corium, LLC | $72.11 | 2024 | Azstarys |
| Almatica Pharma LLC | $63.51 | 2024 | Loreev Xr |
| Teva Pharmaceuticals USA, INC. | $43.60 | 2023-2024 | Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $40.46 | 2024 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $28.77 | 2023 | Quviviq |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $25.76 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.54 | 2024 | Caplyta |
| Biomerieux INC | $19.81 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gaea Pope-Daum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.